
    
      The efficacy and safety of RVT-101 at doses of 70 mg and 35 mg daily will be evaluated over a
      24-week double-blind treatment period in patients with dementia with Lewy bodies.

      The randomization ratio will be 1:1:1 (70 mg RVT-101: 35 mg RVT-101: placebo).

      Subjects completing this study will be eligible to enroll in an extension study of RVT-101
      (Study RVT-101-2002).
    
  